David H. Ilson
0000-0003-0831-2247
Publication & Citation Trends
Publications
0 total
AMIGO: A phase 2 trial of amivantamab in EGFR or MET- amplified gastroesophageal adenocarcinoma (GEA).
Cited by 0
Semantic Scholar
Survival outcomes for phase II study of durvalumab (D) and tremelimumab (T) plus PET-directed chemoradiation (CRT) in patients (Pts) with esophageal adenocarcinoma (EA).
Cited by 0
Semantic Scholar
KEYNOTE-585 Fails While Matterhorn Succeeds in Gastric Cancer: What Lessons Can We Learn?
Cited by 2
Semantic Scholar
Dupilumab for bullous pemphigoid related to immune checkpoint inhibitors: a retrospective case series
Cited by 6
Semantic Scholar
Gastric Cancer, Version 2.2025, NCCN Clinical Practice Guidelines In Oncology.
Cited by 88
Semantic Scholar
3000 Survival and Patterns of Failure in Oligometastatic Esophagogastric Cancer
Cited by 0
Semantic Scholar
Locally advanced microsatellite instability-high esophagogastric cancer: are we ready to change our treatment paradigm?
Cited by 1
Semantic Scholar
Clinical Implications of The Cancer Genome Atlas Molecular Classification System in Esophagogastric Cancer.
Cited by 4
Semantic Scholar
Research Topics
Gastric Cancer Management and Outcomes
(612)
Esophageal Cancer Research and Treatment
(433)
Lung Cancer Treatments and Mutations
(214)
Colorectal Cancer Treatments and Studies
(179)
Cancer Immunotherapy and Biomarkers
(106)
Affiliations
Roche (Switzerland)
Fox Chase Cancer Center
Memorial Sloan Kettering Cancer Center
The University of Texas MD Anderson Cancer Center
Bayer (United States)